CAM
JAZZ icon

Connacht Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Connacht Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,309
Closed -$1.3M – 120
2021
Q2 		$1.3M Sell
7,309
-593
-8% -$103K 0.56% 58
2021
Q1 		$1.3M Buy
+7,902
New +$1.3M 0.29% 83

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Connacht Asset Management's JAZZ Position: Q3 2021 in Review

Connacht Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 7,309 shares — an estimated $1.3M sold.

Connacht Asset Management first reported a position in JAZZ in Q1 2021 and held it in 2 quarters. The position peaked at $1.3M in Q1 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

  • Connacht Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Connacht Asset Management sold 7,309 Jazz Pharmaceuticals shares in Q3 2021, an estimated $1.3M.
  • Connacht Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Connacht Asset Management's Jazz Pharmaceuticals position peaked at $1.3M in Q1 2021.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Connacht Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.